PREDICTION OF TREATMENT OUTCOMES GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of the study was to clarify clinical and morphological criteria for prediction of treatment outcomes gastroenteropancreatic neuroendocrine tumors. Тreatment results were analyzed in 190 patients with neuroendocrine tumors of the pancreas diagnosed in 84 (44,2%), various gastrointestinal tract - 89 (46,3%), liver metastases revealed no localization of primary tumor in 17 (9.5%) of patients. It was determined that the main adverse prognostic factors of the disease are: patient age older than 60 years, tumor localization in the colon and pancreas, the index of proliferative activity (Ki-67) tumor >10%, III-IV stage oncologic process. It is shown that significant prognostic factor in patients with generalized forms of the disease is the possibility of complex treatment allowed to increase the median survival of patients with neuroendocrine tumors 2 times and neuroendocrine carcinomas 2.7 times. The findings suggest that the presence of established clinical and morphological criteria of adverse prognosis of neuroendocrine tumors is advisable a more aggressive treatment option to improve long-term results of treatment and quality of life of patients.

Full Text

Restricted Access

About the authors

P N Romashchenko

S.M. Kirov Military Medical Academy

N A Maistrenko

S.M. Kirov Military Medical Academy

R V Orlova

St. Petersburg State University

M V Lysanuk

S.M. Kirov Military Medical Academy

References

  1. Modlin I.M., Moss S.F., Chung D.C., Jensen R.T., Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine numors // J. Natl. Cancer Inst. 2008. Vol. 100. No 18. P. 1282-1289.
  2. Fraenkel M., Kim M., Faggiano A., de Herder W.W., Valk G.D. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature // Endocrine-Related Cancer. 2014. Vol. 21. No 3. P. 153-163.
  3. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Adalla E.K., Fleming J.B., Vauthey J.-N., Rashid A., Evans D.B. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States // J. Clin. Oncol. 2008. Vol. 26. No 18. P. 3063-3072.
  4. Oberg K.E. Gastrointestinal neuroendocrine tumors // Annals of oncology. 2010. Vol. 21 (Suppl. 7). P. 72-80.
  5. Kloppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms // Endocrine-Related Cancer. 2011. Vol. 18. Р. 1-16.
  6. Lawrence B., Gustafsson B.I., Chan A., Svejda B., Kidd M., Modlin I.M. The epidemiology of gastroenteropancreatic neuroendocrine tumors // Endocrinol. Metab. Clin. N. Am. 2011. Vol. 40. Р. 1-18.
  7. Niederle M.B., Niederle B.N. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation // Oncologist. 2011. Vol. 16. P. 602-613.
  8. Frilling A., Akerstrom G., Falconi M., Pavel M., Ramos J., Kidd M., Modlin I.M. Neuroendocrine tumor disease: an evolving landscape // Endocrine-Related Cancer. 2012. Vol. 19. P. 163-185.
  9. Vinik A.I., Woltering E.A., Warner R.P., Caplin M., O’Dorisio T.M., Wiseman G.A., Coppola D., Go V.W. NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor // Pancreas. 2010. Vol. 39. No 6. Р. 713-734.
  10. Rindi G., Falconi M., Klersy C., Albarello L., Boninsegna L., Buchler M. W., Capella C., Caplin M., Couvelard A., Doglioni C., Delle Fave G., Fischer L., Fusai G., de Herder W.W., Jann H., Komminoth P., de Krijger R.R., La Rosa S., Luong T.V., Pape U., Perren A., Ruszniewski P., Scarpa A., Schmitt A., Solcia E., Wiedenmann B. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study // JNCI. 2012. Vol. 104. No 10. Р. 764-777.
  11. Майстренко Н.А., Ромащенко П.Н., Лысанюк М.В. Нейроэндокринные опухоли поджелудочной железы: проблемы и пути решения // Доктор.Ру. 2014. Т. 100, № 12. С. 62-68 [Maistrenko N.A. Romashchenko P.N., Lisanyuk M.V. Neuroendocrine tumors of the pancreas: problems and solutions, Doctor.Ru. 2014. Vol. 100. No 12. рр. 62-68].
  12. Егоров А.В., Мусаев Г.Х., Фоминых Е.В., Кондрашин С.А., Парнова В.А., Васильев И.А., Лежинский Д.В. Эволюция алгоритма топической диагностики гормонально-активных нейроэндокринных опухолей поджелудочной железы // Анн. хирург. гепатол. 2016. Т. 21, № 1. С. 21-27 [Egorov A.V., Musaev G.H., Fominykh E.V., Kondrashin S.A., Parnova V.A., Vasiliev I.A., Lesinski D.V. Evolution algorithm for diagnostic localization of hormone-active neuroendocrine tumors of the pancreas, Ann. surgeon. gepatol. 2016. Vol. 21. No 1. рр. 21-27].
  13. Майстренко Н.А., Ромащенко П.Н., Лысанюк М.В. Диагностика и хирургическое лечение нейроэндокринных опухолей поджелудочной железы и желудочно-кишечного тракта // Анн. хирург. гепатол. 2016. Т. 21, № 1. С. 13-20 [Maistrenko N.A. Romashchenko P.N., Lisanyuk M.V. Diagnosis and surgical treatment of neuroendocrine tumors of the pancreas and the gastrointestinal tract, Ann. surgeon. gepatol. 2016. Vol. 21. No 1. рр. 13-20].
  14. Bosman F., Carneiro F., Hruban R., Theise N., eds. WHO Classification of tumours of the digestive system. France, Lyon, 2010. P. 13-14.
  15. Klimstra D.S. Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging // Seminars in Oncology. 2013. Vol. 40. No 1. Р. 23-36.
  16. Norlen O., Stalberg P., Oberg K., Eriksson J., Hedberg J., Hessman O., Janson E.T., Hellman P., Akerstrom G. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center // World J. Surg. 2012. Vol. 36. P. 1419-1431.
  17. Lee L., Igarashi H., Fujimori N., Hijioka M. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study // Jap. J. Clinic. Oncol. 2015. Vol. 45. No 12. P. 1131-1138.
  18. Lepage C., Ciccolallo L., De Angelis R., Bouvier A.M., Faivre J., Gatta G. European disparities in malignant digestive endocrine tumours survival // Int. J. Cancer. 2010. Vol. 126. P. 2928-2934.
  19. Schimmack S., Svejda B., Lawrence B., Kidd M., Modlin I.M. The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors // Langenbecks Arch. Surg. 2011. Vol. 396. No 3. P. 273-298.
  20. D’Haese J.G., Tosolini C., Ceyhan G.O., Kong B., Esposito I., Michalski C.W., Kleeff J. Update on surgical treatment of pancreatic neuroendocrine neoplasms // World J. Gastroenterol. 2014. Vol. 20. No 38. Р. 13893-13898.
  21. Paniccia A., Edil B.H., Schulick R.D. Pancreatic Neuroendocrine Tumors: an Update // Indian J. Surg. 2015. Vol. 77. No 5. Р. 395-402.
  22. Partelli S., Maurizi A., Tamburrino D., Baldoni A., A. Baldoni, Polenta V., Crippa S., Falconi M. A review on surgery of gastro-entero-pancreatic neuroendocrine tumors // European Journal of Endocrinology. 2014. Vol. 171. No 4. P. 153-162.
  23. Jann H., Roll S., Couvelard A., Hentic O., M. Pavel, J. Müller-Nordhorn, M. Koch, C. Röcken, G. Rindi, P. Ruszniewski, B. Wiedenmann, U.-F. Pape. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome // Cancer. 2011. Vol. 117. No 15. P. 3332-3341.
  24. Ter-Minassian M., Chan J.A., Hooshmand S.M., Brais L.K., Daskalova A., Heafield R., Buchanan L., Z.R. Qian Fuchs C.S., Lin X., Christiani D.C., Kulke M.H. Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database // Endocrine-Related Cancer. 2013. Vol. 20. Р. 187-196.
  25. Yang P., Liu J., Lin D., Fu H., Chu J., Li F., Han G., Li Y., Fu W. Clinical characteristics and prognostic analysis of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) // Chinese-German J. Clin. Oncol. 2014. Vol. 13. No 12. P. 578-583.
  26. Russolillo N., Vigano L., Razzore P., Langella S., Motta M., Bertuzzo F., Papotti M., Ferrero A. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations // EJSO. 2015. Vol. 41. No 6. P. 751-757.
  27. Jiao X., Li Y., Wang H., Liu S., Zhang D., Zhou Y. Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China // Chin. J. Cancer Res. 2015. Vol. 27. No 3. Р. 258-266.
  28. Crippa S., Zerbi A., Boninsegna L., Capitanio V., Partelli S., Balzano G., Pederzoli P., Di Carlo V., Falconi M. Surgical Management of Insulinomas. Short- and Long-term Outcomes After Enucleations and Pancreatic Resections // Arch. Surg. 2012. Vol. 147. No 3. P. 261-266.
  29. Tavсar I., Kikoviс S., Bezmareviс M., Rusoviс S., Perisic N., Mirkovic D., Kuzmic-Jankovic S., Dragovic T., Karajovic J., Sekulovic L., Hajdukovic Z. A 60-year expirience in the treatment of pancreatic insulinoma in the Military Medical Academy, Belgrade, Serbia // Vojnosanit Pregl. 2014. Vol. 71. No 3. Р. 293-297.
  30. Moller J.E., Pellikka P.A., Bernheim A.M., Schaff H.V., Rubin J., Connolly H.M. Prognosis of carcinoid heart disease analysis of 200 cases over two decades // Circulation. 2005. Vol. 112. P. 3320-3327.
  31. Modlin I.M., Gustafsson B.I., Moss S.F., Pavel М., Tsolakis A.V., Kidd M. Chromogranin A - biological function and clinical utility in neuroendocrine tumor disease // Ann. Surg. Oncol. 2010. Vol. 17. P. 2427-2443.
  32. Oberg K., Krenning E., Sundin A., Bodei L. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management // Endocrine Connections. 2016. Vol. 175. No 5. Р. 174-187.
  33. Ekeblad S., Skogseid B., Dunder K., Oberg K., Eriksson B. Prognostic Factors and Survival in 324 patients with pancreatic endocrine tumor treated at a single institution // Clin. Cancer Res. 2008. Vol. 14. No 23. Р. 7798-7803.
  34. Arnold R., Wilke A., Rinke A., Mayer C. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors // Clin. Gastroenterol. Hepatol. 2008. No 6. Р. 820-827.
  35. Yao J.C., Pavel M., Phan A.T., Kulke M.H., Hoosen S., Peter J., Cherfi A., Öberg K.E. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus // J. Clin. Endocrinol. Metab. 2011. Vol. 96. No 12. P. 3741-3749.
  36. Khan M.S., Kirkwood A., Tsigani T., Garcia-Hernandez J., Hartley J.A., Caplin M.E., Meyer T. Circulating tumor cells as prognostic markers in neuroendocrine tumors // J. Clin. Oncol. 2013. Vol. 31. No 3. P. 365-372.
  37. Miller H.C., Drymousis P., Flora R., Goldin R., Spalding D., Frilling A. Role of Ki-67 Proliferation Index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease // World J. Surg. 2014. No 38. P. 1353-1361.
  38. Hentic O., Couvelard A., Rebours V., Zappa M., Dokmak S., Hammel P., Maire F., O’Toole D., Levy P., Sauvanet А., Ruszniewski P. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas // Endocrine-Related Cancer. 2011. No 18. P. 51-59.
  39. Yamaguchi T., Fujimori T., Tomita S., Ichikawa K., Mitomi H., Ohno K., Shida Y., Kato H. Clinical validation of the gastrointestinal NET grading system: Ki67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrence // Diagn. Pathol. 2013. Vol. 65. No 8 Р. 1-7.
  40. Richards-Taylor S., Ewings S.M., Jaynes E., Tilley C., Ellis S.G., Armstrong T., Pearce N., Cave J. The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis // J. Clin. Pathol. 2016. Vol. 69. No 7. Р. 612-618.
  41. Hauck L., Bitzer M., Malek N., Plentz R.R. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors // Scandinavian J. Gastroenterol. 2016. No 51. P. 55-59.
  42. Caplin M.E., Pavel M., Cwikła J.B., Phan A.T. Lanreotide in metastatic enteropancreatic neuroendocrine tumors // N. Engl. J. Med. 2014. Vol. 371. P. 224-233.
  43. Basturk O., Yang Z., Tang L.H., Hruban R.H. The high grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneosus and includes both well differentiated and poorly differentiated neoplasms // Am. J. Surg. Pathol. 2015. Vol. 39. No 5. P. 683-690.
  44. Haugvik S.-P., Janson E.T., Osterlund P., Langer S.W. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study // Ann. Surg. Oncol. 2016. No 23. P. 1721-1728.
  45. Sorbye H., Welin S., Langer S.W., Vestermark L.W. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study // Ann. Oncol. 2013. No 24. P. 152-160.
  46. Heetfeld M., Chougnet C.N., Olsen I.H., Rinke A., I. Borbath, Crespo G., Barriuso J., Pavel M., O’Toole D., Walter T. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms // Endocrine-Related Cancer. 2015. Vol. 22. No 4. P. 657-664.
  47. Milione M., Maisonneuve P., Spada F., Pellegrinelli A., Spaggiari P., Albarello L., Pisa E., Barberis M., Vanoli A., Buzzoni R., Pusceddu S., Concas L., Sessa F., Solcia E., Capella C., Fazio N., La Rosa S. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories // Neuroendocrinol. 2017. Vol. 104. P. 85-93.
  48. Fischer L., Bergmann F., Schimmack S., Hinz U., Prie S., Muller-Stich B.P., Werner J., Hackert T., Buchler M.W. Outcome of surgery for pancreatic neuroendocrine neoplasms // BJS. 2014. Vol. 101. P. 1405-1412.
  49. Shiba S., Morizane C., Hiraoka N., Sasaki M., Koga F., Sakamoto Y., Kondo S., Ueno H., Ikeda M., Yamada T., Shimada K., Kosuge T., Okusaka T. Pancreatic neuroendocrine tumors: a single-center 20-year experience with 100 patients // Pancreatology. 2016. Vol. 16. No 1. P. 99-105.
  50. Strosberg J.R., Cheema A., Weber J., Han G., Kvols L.K. Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors // J. Clin. Oncol. 2011. Vol. 29. No 22. P. 3044-3049.
  51. Janot M.S., Kersting S., Herzog T., Chromik A.M., Uhl W. Prognosis and Long-Term Survival after Operation in Patients with Pancreatic and Peripancreatic Neuroendocrine Tumors of a Single Center // J. Pancreas (Online). 2016. Vol. 17. No 2. Р. 182-188.
  52. Bertani E., Falconi M., Grana C., Botteri E., Chiappa A., Misitano P., Spada F., Ravizza D., Bazolli B., Fazio N. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: prognostic factors for decision making // International Journal of Surgery. 2015. No 20. P. 58-64.
  53. Panzuto F., Merola E., Rinzivillo M., Partelli S. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome // Pancreas. 2014. Vol. 43. No 2. Р. 212-218.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Romashchenko P.N., Maistrenko N.A., Orlova R.V., Lysanuk M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies